← Back to Search

Virus Vaccine

Shingrix Vaccine for Shingles

Phase 2
Waitlist Available
Led By Nadine Rouphael, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 from day 0, day 7 from day 0, day 61 from day 60, day 67 from day 60
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to understand how the immune system responds to the Shingrix® vaccine in older adults. The study will involve healthy participants in two different age groups. The vaccine helps the body build defenses against the virus that causes shingles, preventing its reactivation. Shingrix® is a newer version of the shingles vaccine that has shown promising results in many studies.

Eligible Conditions
  • Shingles
  • Varicella
  • Chickenpox

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 from day 0, day 7 from day 0, day 61 from day 60, day 67 from day 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 from day 0, day 7 from day 0, day 61 from day 60, day 67 from day 60 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Innate Immune Signatures Post-vaccine Dose
Secondary study objectives
Safety of Zoster Vaccine Recombinant, Adjuvanted

Side effects data

From 2023 Phase 2 trial • 38 Patients • NCT04047979
7%
Upper Respiratory Infection
3%
Rash maculo-papular
3%
Ureteroscopy with lithotripsy
3%
Hypertension emergency
3%
Peripheral Neuropathy
3%
Automobile accident
3%
Allergic rhinitis
3%
Vertigo
3%
Reconstructive surgery 3rd, 4th, 5th phalange
3%
Itching
100%
80%
60%
40%
20%
0%
Study treatment Arm
Younger Group
Older Group

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Younger GroupExperimental Treatment1 Intervention
Participants between the ages of 50 to 60 years will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
Group II: Older GroupExperimental Treatment1 Intervention
Participants who are ≥70 year old will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Shingrix®
2019
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,708 Previous Clinical Trials
2,607,446 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,336 Previous Clinical Trials
5,392,796 Total Patients Enrolled
Nadine Rouphael, MDPrincipal Investigator - Emory University
Emory University Hospital Midtown, Select Specialty Hospital-Atlanta
St Joseph'S University (Medical School)
Emory University School Of Medicine (Residency)
16 Previous Clinical Trials
849 Total Patients Enrolled

Media Library

Shingrix® (Virus Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04047979 — Phase 2
Shingles Research Study Groups: Younger Group, Older Group
Shingles Clinical Trial 2023: Shingrix® Highlights & Side Effects. Trial Name: NCT04047979 — Phase 2
Shingrix® (Virus Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04047979 — Phase 2
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top